Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04321161 | Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | completed | Early Phase 1 | 10 | University of FreiburgOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | withdrawn | Early Phase 1 | 0 | Michael BoyiadzisOTHER | 1 | Apr 19, 2019 | clinicaltrials |
| NCT00212407 | New York Blood Center National Cord Blood Program | terminated | Early Phase 1 | 4,476 | New York Blood CenterOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03228303 | Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Early Phase 1 | 100 | Assiut UniversityOTHER | 0 | Oct 10, 2017 | clinicaltrials |
| NCT02805868 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | withdrawn | Early Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Oct 24, 2016 | clinicaltrials |
| NCT02117115 | Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation(GVHD) | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00437086 | Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 17, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Mar 25, 2020source: clinicaltrials